Jade Biosciences, Inc (JBIO)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Jade Biosciences, Inc (JBIO) is up 26.1% since the beginning of the year. At $19 per share, JBIO is trading 30.5% below its 52-week high of $28.

Jade Biosciences, Inc (JBIO) has returned 26.05% so far this year and 96.66% over the past 12 months.

Based on dividend-adjusted daily data since Jun 30, 2021, JBIO's average daily return is +2.97%, while the average monthly return is +60.18%. At this rate, an investment would double in approximately 0.1 years.

Historically, 52% of months were positive and 48% were negative. The best month was Apr 2025 with a return of +3,522.7%, while the worst month was Jun 2024 at -90.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 3 months.

On a daily basis, JBIO closed higher 49% of trading days. The best single day was Apr 29, 2025 with a return of +3,521.4%, while the worst single day was Jun 17, 2024 at -93.3%.

Jade Biosciences, Inc has an annualized alpha of 117159.87%, beta of 2.46, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since June 30, 2021.

• This stock tended to rise when S&P 500 Index fell (downside capture of -904.34%), but participation in market rallies was also limited (-43.70%) - a profile typical of counter-cyclical assets.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

JBIO ranks 76 for risk / return — better than 76% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

Jade Biosciences, Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.

The table displays the monthly dividend distributions for Jade Biosciences, Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Jade Biosciences, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jade Biosciences, Inc was 95.41%, occurring on Jun 18, 2024. Recovery took 215 trading sessions.

The current Jade Biosciences, Inc drawdown is 27.56%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Jade Biosciences, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Jade Biosciences, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.